Opinion|Videos|September 18, 2024
Integrating PD-1 Inhibitors into Standard NPC Treatment: Potential Benefits and Future Prospects
Victoria M. Villaflor, MD, discusses the integration of PD-1 inhibitors into standard treatment practices for patients with nasopharyngeal carcinoma.
Advertisement
Episodes in this series
Video content above is prompted by the following:
What are the potential benefits of integrating PD-1 inhibitors into standard treatment protocols for NPC?
- What does the future look like for PD-1 Inhibitors in NPC?
Advertisement
Related to this article
Tenumomeran/raplemomeran plus pembrolizumab missed the PFS end point in HPV16-positive HNSCC.
Adjuvant TG4050 was well tolerated and generated long-lasting neoantigen-specific T-cell responses in resected HPV-negative HNSCC.
PRV111 produced pathologic complete responses in 21 of 22 patients with noninvasive oral cancer or high-grade dysplasia.
The combination nearly doubled the confirmed response rate in the randomized phase 2 portion of HexAgon-HN, with the greatest benefit in HPV-positive disease.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Nogapendekin Alfa Inbakicept Plus BCG for High-Grade, Papillary-Only BCG-Unresponsive NMIBC
2
SurVaxM Cancer Vaccine Shows Clinically Meaningful OS Signal in Newly Diagnosed Glioblastoma
3
VS-7375 Elicits Responses in KRAS G12D–Mutated Pancreatic Cancer
4
FDA Accepts BLA Resubmission for Tabelecleucel in EBV+ Post-Transplant Lymphoproliferative Disease
5